Carbamazepine Patent Expiration
Carbamazepine is Used for treating neurological and other disorders such as epilepsy with twice daily oral dosing. It was first introduced by Novartis Pharmaceuticals Corp
Carbamazepine Patents
Given below is the list of patents protecting Carbamazepine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Carnexiv | US11529357 | Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine | Jan 31, 2040 | Lundbeck Pharms Llc |
| Carnexiv | US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | Feb 27, 2033 | Lundbeck Pharms Llc |
| Carnexiv | US7635773 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Lundbeck Pharms Llc |
| Carnexiv | US8410077 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Lundbeck Pharms Llc |
| Carnexiv | US9750822 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Lundbeck Pharms Llc |
| Carnexiv | US9629797 | Parenteral carbamazepine formulation | Nov 10, 2028 | Lundbeck Pharms Llc |
| Carnexiv | US9770407 | Parenteral carbamazepine formulation | Nov 10, 2028 | Lundbeck Pharms Llc |
| Equetro | US6977253 | Methods for the treatment of bipolar disorder using carbamazepine |
May 19, 2024
(Expired) | Validus Pharms |
| Carbatrol | US5912013 | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
Jun 15, 2016
(Expired) | Takeda Pharms Usa |
| Equetro | US5912013 | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
Jun 15, 2016
(Expired) | Validus Pharms |
Carbamazepine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Carbamazepine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
